Can Olive Leaf Polyphenols Slow the Biology Behind Postmenopausal Skin Aging?

Study Overview

The study, “Effects of olive leaf extract supplementation on systemic markers of tissue aging and remodeling in postmenopausal women: a randomized controlled trial with exploratory skin outcomes,” was published in Frontiers in Nutrition in 2025 by Anissa Lasfar and colleagues. It was a randomized, double-blind, placebo-controlled, parallel trial conducted at Maastricht University and registered as NCT05744453.

Sixty-five healthy postmenopausal women aged 45-70 were randomized to 250 mg/day olive leaf extract or placebo for 12 weeks. Sixty participants were included in the reported analysis: 29 in the olive leaf extract group and 31 in placebo. The supplement was Bonolive®, an olive leaf extract standardized to more than 40% oleuropein. In practical dose terms, each capsule provided at least 100 mg oleuropein per day.

The researchers measured circulating markers of tissue aging and remodeling: serum elastin, pro-collagen type I alpha 1, plasma hydroxyproline, serum matrix metalloproteinase-2 (MMP-2), fasting glucose, and protein-bound advanced glycation end-products. A smaller subgroup of 26 participants also underwent facial skin assessment with a C-Cube video dermoscope, which quantified pore number, surface texture, wrinkles, redness, pigmentation, hair measures, and related skin characteristics.

Key Findings: The Actual Numbers

The trial is most useful because it separates nominal signals from corrected significance. Serum elastin rose in the placebo group from 73.3 ± 19.6 ng/mL at baseline to 80.5 ± 25.4 ng/mL at 12 weeks, while remaining broadly stable in the olive leaf extract group: 69.0 ± 18.9 to 68.5 ± 20.4 ng/mL. The modeled OLE-placebo treatment effect was -6.3 ng/mL (95% CI -12.0 to -0.5; p = 0.033), but after false-discovery-rate correction it became a trend rather than a formal positive finding (adjusted p = 0.0825).

Pentosidine, an advanced glycation end-product linked to protein cross-linking and tissue stiffening, showed a similar pattern. In the OLE group, pentosidine moved from 8.9 ± 3.2 to 8.1 ± 2.5 nmol/L; placebo moved from 8.4 ± 2.1 to 8.5 ± 2.5 nmol/L. The treatment effect was -0.751 nmol/L (95% CI -1.4 to -0.11; p = 0.022), but again missed corrected significance (adjusted p = 0.088). Collagen, hydroxyproline, MMP-2, fasting glucose, CML, CEL, and MG-H1 were not meaningfully changed.

The clearest statistically significant result came from the exploratory skin subgroup. Pore number showed a significant time-by-treatment interaction (p = 0.004). Within the olive leaf extract group, pore number fell from 27.7 ± 8.4 at week 6 to 14.8 ± 8.6 at week 12 (post-hoc difference -12.9; p = 0.0012), whereas placebo did not change meaningfully. At week 12, the OLE group had significantly lower pore number than placebo, with a mean difference of -7.86 (p = 0.034). Surface skewness also improved within the OLE group from week 6 to week 12 (-0.32; p = 0.0166), but the week-12 comparison versus placebo was only a trend (p = 0.0847).

Mechanism: Why Olive Leaf Might Affect Tissue Aging

Olive leaf extract is not simply “olive oil in capsule form.” It is a more concentrated phenolic intervention, dominated here by oleuropein: the authors report oleuropein as 83.88% of the extract’s quantified polyphenol profile, with smaller amounts of hydroxytyrosol, hydroxytyrosol glucoside, verbascoside, rutin, luteolin derivatives, and other olive-leaf compounds.

The mechanistic logic is plausible. Postmenopausal tissue aging is partly driven by estrogen decline, oxidative stress, extracellular-matrix remodeling, and glycation. Glycation creates advanced glycation end-products such as pentosidine, which can cross-link collagen and other structural proteins, making tissue less elastic. Oxidative stress can amplify that process and activate matrix metalloproteinases, including MMP-2, which participate in extracellular-matrix breakdown.

Oleuropein and hydroxytyrosol-related metabolites have antioxidant and anti-inflammatory effects in experimental models. If they reduce oxidative pressure and protein glycation, you could imagine slower elastin breakdown or better preservation of surface skin structure. This trial does not prove that full pathway; MMP-2 and several glycation markers were unchanged. But the pentosidine and skin-texture signals are directionally consistent with the biology rather than random marketing language.

Context: How This Compares With Previous Research

Most olive-polyphenol human studies focus on cardiovascular or metabolic endpoints: blood pressure, oxidized LDL, lipids, inflammation, insulin sensitivity, endothelial function, and post-meal oxidative stress. Skin and connective-tissue outcomes are much less developed. That makes this paper interesting, but also easy to overstate.

The study fits with the broader olive-polyphenol pattern: the most believable effects tend to show up where oxidative stress, inflammation, lipid oxidation, vascular biology, or protein damage are involved. It also links to earlier work from the same trial, which reported improvements in menopause-specific quality-of-life symptoms, right-arm bone mineral density, triglycerides, and triglyceride/HDL ratio. Taken together, the program suggests a systemic postmenopausal-aging hypothesis, not just a cosmetic claim.

Compared with stronger cardiometabolic RCTs, however, this paper is smaller and more exploratory. The best olive leaf blood-pressure trials report cleaner clinical endpoints, such as home or 24-hour blood pressure. Here, the clinical meaning of fewer dermoscope-counted pores is less direct. The study is valuable because it brings measurement discipline to a fluffy category, not because it proves olive leaf extract is a skin-aging therapy.

Limitations

• • Small trial: only 60 women were analyzed, with just 26 in the skin-imaging subgroup.
• • Multiple-testing issue: elastin and pentosidine were nominally significant but did not remain significant after FDR correction.
• • Exploratory skin outcomes: the skin subgroup was not the primary powered endpoint, so pore and texture results need replication.
• • Healthy population: participants were healthy postmenopausal women with BMI below 35; results may not generalize to metabolic disease, smokers, hormone therapy users, or people with skin disease.
• • Industry involvement: the extract was supplied by Solabia BV; several authors were Solabia employees, and one was an inventor on a Solabia patent application.
• • Product specificity: this was Bonolive olive leaf extract standardized to oleuropein, not ordinary olive oil and not a generic supplement.

Our Take

This is a good example of a study that is more interesting than it is definitive. The design is respectable: randomized, double-blind, placebo-controlled, with fasting blood draws, blinding, independent randomization, and explicit correction for multiple testing. The authors deserve credit for not pretending that every p-value is equally strong.

The honest read is this: olive leaf extract may be nudging postmenopausal tissue-aging biology, especially glycation and local skin morphology, but the systemic evidence is still trend-level. The pore-number result is intriguing, yet the subgroup is too small to carry a consumer claim on its own. If a supplement brand used this paper to say “clinically proven to reverse skin aging,” we would call that an overreach.

Still, the paper belongs in the olive-polyphenol evidence map because it expands the conversation beyond cholesterol and blood pressure. It suggests that olive phenolics may interact with protein damage, extracellular-matrix preservation, and visible tissue structure — exactly the biology that makes olive-derived compounds interesting for long-term health. The next study should be larger, independently funded, pre-specify skin endpoints, and compare olive leaf extract with high-polyphenol EVOO rather than placebo alone.

Reference

Lasfar A, van Stratum SLM, Imperatrice M, van Kalkeren CAJ, Scheijen JLJM, Schalkwijk CG, La Torre D, Troost FJ. Effects of olive leaf extract supplementation on systemic markers of tissue aging and remodeling in postmenopausal women: a randomized controlled trial with exploratory skin outcomes. Frontiers in Nutrition. 2025;12:1670194. doi: 10.3389/fnut.2025.1670194. PMID: 41340653. PMCID: PMC12671197.